Several genetic diseases, generally considered as congenital diseases, are characterized by bone marrow failure during early childhood. Hematopoietic stem cell transplantation is the only curative treatment for syndromes involving bone marrow failure and thalassemia. In this slate-of-the-art review, we wish to focus on the results of hematopoietic transplantation in treating some of these diseases, with a special emphasis on congenital bone marrow failure and thalassemia. The results of this procedure have improved over the previous years, mainly when performed by experienced teams. New conditioning regimes based on fludarabine and the use of HLAidentical donors have been related with better survivals. In the previous years, donors other than HLA-identical siblings have been increasingly used in patients not responding to conventional measures, but this approach needs to be evaluated in larger studies. Bone Marrow Transplantation (2005) 35, S17-S21.
Several genetic diseases, generally considered as congenital diseases, are characterized by bone marrow failure during early childhood (Table 1 ). Although they have recently been addressed in different reviews, 1,2 here we wish to focus on the results of hematopoietic transplantation in treating some of these diseases, with a special emphasis on congenital bone marrow failure and thalassemia.
Congenital bone marrow failure

Fanconi anemia
Fanconi anemia (FA) is a heterogeneous disorder characterized by bone marrow failure, susceptibility to cancer, and hypersensitivity to alkylating agents. It is an autosomal recessive disease and diagnosis of FA homozygotes is confirmed by the detection of chromosome aberrations in lymphocytes (or fibroblasts) following culture with crosslinking agents (diepoxybutane or mitomycin C). To date, 11 complementation groups have been identified and eight FA genes have already been cloned ( Table 2) . 3 Hematopoietic cell transplantation is the only treatment that can cure the bone marrow aplasia in patients with FA. Nevertheless, while this problem is the earliest and most frequent life-threatening complication, severe birth defects and cancer predisposition must also be taken into account in children with FA. Hematopoietic progenitor cell transplantation in patients with FA has been limited in the past by high rates of graft failure, regimen-related toxicity, and acute and chronic graft-versus-host disease. Furthermore, recent studies have found that the risk of some malignancies appearing is higher in patients after transplantation than in patients who did not undergo transplantation. 4 It is well known that patients with FA are highly susceptible to alkylating agents and irradiation. Therefore, it has been suggested that the dose of cyclophosphamide could be decreased in order to improve survival, as well avoiding the use of irradiation in the conditioning regime. Low-toxicity regimes (nonmyeloablative) with fludarabine have achieved very good results with HLA-identical donors, 5 and indeed this regime achieved 100% event-free survival in one series of patients when combined with T-cell-depleted grafting. 6 When alternative donors are used, some authors consider that higher myeloablative regimens are necessary. In this scenario, irradiation and fludarabine lead to 76% overall survival in a standard risk group (less than 18 years old, absence of acute leukemia or myelodysplastic syndrome (MDS), and HLA-matched bone marrow or cord blood). 6 However, there is as yet no consensus regarding the use of irradiation with these patients and some groups have avoided its use with good results even when unrelated donors are involved. Indeed, the severe aplastic anemia working party of the EBMT has recently reported 85% overall survival for children under 8 years of age after hematopoietic transplantation with alternate donors. In this protocol, the conditioning regime involved fludarabine 30 mg/m 2 , cyclophosphamide 300 mg/m 2 , and ATG 3.75 mg/kg for 4 days. 7 A similar regime was also described by de la Fuente et al 8 in four children diagnosed with FA. Progenitor cells from unrelated donors were used in two patients, and HLA-matched sibling donors in the other two children. Full donor grafting was achieved in the first month after transplantation with minimal toxicity in all of these cases, and at 11, 23, 30, and 51 months after transplantation they were alive and well (Karnofsky 100%). 8 In other studies, encouraging results have also been reported with other fludarabine-based conditioning regimes. 5, 9 While progenitor cells obtained from bone marrow are the most frequently used for patients diagnosed with FA, in some cases transplants have been performed with stem cells collected from peripheral blood. However, to date, no indepth comparison of these two stem cell sources has been performed. The experiences of the Eurocord registry involving 44 patients diagnosed with FA have recently been reported, 10 seven of which were transplanted from HLA-identical donors and 37 from nonidentical donors. The overall survival for these patients was 36% after 2 years, and this appeared to be related to the number of nucleated cells at freezing (45.5 Â 10 7 /kg, 55 vs 16%) and the use of fludarabine in the preparative regime (67 vs 25%). Indeed, the overall survival in this study is similar to that reported earlier by Guardiola et al 11 with bone marrow stem cells from unrelated donors in a study on behalf of the European group for blood and marrow transplantation. Therefore, this source of stem cells may expand the possibility of finding an unrelated donor for children that would otherwise be unable to undergo transplantation. Moreover, with a better selection of the cord blood and the use of fludarabine in the conditioning regime, these results may improve in the near future. 10 
Other congenital bone marrow failures
Recently, encouraging results have been reported when hematopoietic transplants have been performed in patients diagnosed with Severe Congenital Neutropenia 12,13 and Diamond-Blackfan Anemia 14 (DBA). Indeed, the 'International Bone Marrow Transplant Registry' recently presented their experiences with DBA 14 in which they reviewed the outcome of 61 patients registered after receiving allogeneic bone marrow transplants for DBA. 14 The probability of overall survival was 67% (54-77%) after 1 year and remained at 64% (50-74%) after 3 years. In a univariant analysis, a Karnofsky score X90 was associated with better overall survival for 100 days (93 vs 63%, Po0.01) and for 3 years (75 vs 42%, P ¼ 0.01).
14 Similarly, transplants from a HLA-identical sibling were associated with higher survival than those using an alternative donor, the survival being 78 vs 45% after 1 year (P ¼ 0.01) and 75 vs 39% after 3 years (P ¼ 0.01). 14 The availability of G-CSF dramatically changes the prognosis of severe congenital neutropenia and the quality of life of these patients. However, almost 10% of patients are refractory to this therapy and, for them, the only treatment available is hematopoietic transplantation.
12 This is also the only curative treatment for those patients who develop MDS or acute leukemia (AL), and those who have mutations in the G-CSF receptor, since this seems to play an important role in the development of leukemia. 12 All patients reported in the International Severe Chronic Neutropenia register who received a transplant from a sibling donor without evidence of leukemic transformation were still alive at the time the study was published (8/8). This is the best scenario, since the prognosis was not so good for those patients who developed MDS/AL. Recently, Zeidler et al 13 reviewed this topic at the ASH meeting and suggested that hematopoietic transplantation should be performed as early as possible. The main objective is to prevent infection before transplantation and therefore intensive AML-type chemotherapy should be avoided. 13 Indeed, these authors suggested using low-dose chemotherapy to control the neoplastic clone until hematopoietic transplantation could be performed. 13 This improves the results from the 31% reported by the international database up to the end of 2000, to the 59% reported in a European cohort of patients. 13 For 'Severe Congenital Neutropenia' and DBA, the problem of the optimal timing of transplantation is constantly under debate since some of these patients can be controlled for years with supportive therapies. However, it seems clear that for those cases that are nonresponsive to medical therapies and where a matched sibling donor is available, stem cell transplantation should be performed rapidly in order to decrease transplant-related mortality. Transplantation from donors other than a matched sibling donor should be considered on a case-by-case basis when individual circumstances justify the risk.
Stem cell transplantation for thalassemia
The EBMT registry included 2312 patients from 112 different centers diagnosed with thalassemia, who had undergone hematopoietic transplantation by April 2004. Most transplants were performed using only bone marrow as the stem cell source (90%) and most of them had a matched related donor (90%; Dr Angelucci, EBMT, 2004). In Pesaro, Dr Guido Lucarelli and his group first began to use bone marrow transplantation in selected patients with this disease in 1981, and, over the last 20 years, 1003 patients have been transplanted in their unit from a matched related donor. As a result, most of our current knowledge regarding the use of this therapy for thalassemia has been generated by this group. Initially, all patients received a conditioning regime involving total doses of cyclophosphamide of 200 mg/kg and 14-16 mg/kg of busulfan. In patients younger than 17 years of age, the results of this protocol led to their classification into three different risk groups according to the appearance of hepatic disease secondary to iron deposition and hepatomegaly. The thalassemia-free survival in these groups varied from 94% for patients in group 1, to 77% for those in group 2, and 53% for patients in group 3. 15 In order to reduce the toxicity in patients in group 3 associated with the conditioning regime, the total dose of cyclophosphamide was reduced to 120-160 mg. This modification in the protocol increased the overall survival to 57% with the higher doses of cyclophosphamide or 74% with the lower doses. However, the probability of rejection also increased from 13% to 35% and, as a result, there was no improvement in thalassemia-free survival (53 vs 49%). 16 Furthermore, older patients treated with lower doses of cyclophosphamide, who were included in risk groups 2 or 3, only achieved 62% thalassemia-free survival and an overall survival of 66%. 17 An update of these data showed a nonrejection-related mortality rate for older patients of 36%, while in patients below 17 years of age it was only 18%. 18 Hence, it is clear from both studies that the main problem for younger patients is the rate of rejection. Thus, while the results were optimal for younger patients belonging to risk groups 1 and 2, the challenge then was to improve the results in older patients and those with liver disease.
Based on prior experiences, the regime for patients classified in risk group 3 was modified in 1997, 19 involving hypertransfusion and intensive iron chelation, and hydroxyurea 30 mg/kg daily and azathioprine 3 mg/kg daily between days À45 and À11. The aim was to reduce the expansion of the immature red blood cells and eradicate the marrow. Subsequently, fludarabine was added (20 mg/m 2 from day À17 through to day À13) because of its immunosuppressive and bone-marrow-suppressive activities. Additionally, busulfan 1 mg/kg/dose in three doses per day was administered for 5 days (À10 through to À6, total dose 14 mg/kg), and cyclophosphamide 40 mg/kg daily (À5 through to À2, total dose 160 mg/kg). 16 For graftversus-host disease prophylaxis, the following regime was followed: cyclophosphamide 7.5 mg/kg on day 1; methotrexate 10 mg/m 2 intravenously on days 3 and 6; cyclosporine 5 mg/kg from day À2 through to day 5, and then reduced to 3 mg/kg intravenously until oral administration could be tolerated; and prednisolone 0.5 mg/kg from day À1 until day 25. With this new regime, the probability of overall survival was 93% and thalassemia-free survival improved to 85%. 16 Moreover, the probability of rejection was reduced to 8% and nonrejection mortality to 6%, 16 results similar to those obtained for risk groups 1 and 2 with the initial protocols. For adult patients in this group, a new conditioning regime was also developed that was similar to that used for younger patients, but with a total dose of cyclophosphamide of 90 mg/kg. However, the results of using such a regime have yet to be reported.
Thus, it seems that we have overcome the challenge to improve the treatment for group 3 patients, such that the new challenges will focus on those patients lacking a matched related donor.
Unrelated transplants
The first protocol using unrelated donors to treat thalassemia was reported by Contu et al in 1994, 20 although the largest published study on this subject, which includes 32 patients, has only just recently been published. 21 In this study, La Nasa et al reported the results of using unrelated donors for bone marrow transplants after a careful immunogenetic selection of the donor/recipient pairs. Among these patients, four were assigned to risk class 1, 11 to risk class 2, and 17 to risk class 3, and not all patients received the same conditioning regime. Initially, total doses of cyclophosphamide 200-160 mg/kg and busulfan 14 mg/ kg were used in four patients, but since graft failure occurred in two of them, thiotepa 10 mg/kg was added to this protocol. Finally, cyclophosphamide was reduced to a total dose of 120 mg/kg in those patients over 16 years of age. In this study, the Kaplan-Meier probability of survival was 79% and the thalassemia-free survival was 66%. Of the 22 patients that the authors considered had an optimal donor, 19 were still alive and 17 of them did not require transfusions. Only two patients developed a rejection of the graft after thiotepa was added to the protocol. In this study, there were six transplant-related deaths, and, although not statistically significant, five of them belong to risk class 3, and one to group 1.
More recently, the results from a series of 11 patients with thalassemia who received transplants from unrelated donors have been published. 22 The patients underwent bone marrow transplantation following a conditioning regime with cyclophosphamide (200 mg/kg total dose) and busulfan (16 mg/kg total dose), as well as the addition of antilymphocyte globulin (40 mg/kg total dose) to this regime. Most of the patients were classified in risk class 1 (eight), while only two were assigned to risk class 3. In all, 10 donors were identical at molecular level to the recipients for HLA-A, -B, and -DRB1, and only one patient was mismatched at for an HLA-DRB1 allele. The graft-versushost disease prophylaxis consisted of methotrexate and cyclosporine. At the time of publication, all patients had full donor engraftment and were alive. However, three patients (27%) developed chronic limited graft-versus-host disease in this series. 22 While this study needs to be expanded in terms of the number of patients, it does provide 'additional evidence to support the view that is quite reasonable to consider unrelated donor BMT as an acceptable therapy to cure thalassemia, at least for patients who are young and do not yet show irreversible severe complications of iron overload', as the authors point out. 19 
Other sources of stem cells
The experiences of 'Eurocord' were published in 2003, 23 where 44 patients diagnosed with SCD or thalassemia underwent transplantation using cord blood as the stem cell source. In all, 33 thalassemic patients (20 risk class I, and 13 class II) and 11 patients diagnosed with SCD received a related cord blood transplant with a graft probability of 89%, aGVHD 8%, and cGHVD 6%. The probability of event-free survival was 79% for the subjects with thalassemia and 90% for those with SCD. Survival was related to the use of methotrexate, since the event-free survival was lower in those patients in whom it was used for GVHD prophylaxis than in those whom did not receive this drug. There was also a trend but not a significant association between a higher event-free survival in risk group I thalassemia patients, and in those whose conditioning regime did not involve busulfan-cyclophosphamide alone. 23 
Lower-toxicity conditioning regimes
There is little information regarding nonmyeloablative regimes for hematopoietic transplantation in hemoglobinopathies. Conditioning regimes based on fludarabine, with low-dose busulfan or total body irradiation (200 cGy), have been used in these diseases. 24 Indeed, seven patients diagnosed with hemoglobinopathies who underwent a nonmyeloablative conditioning regime for hematopoietic transplantation experienced autologous hematopoietic recovery. 24 
Conclusion
Hematopoietic stem cell transplantation is the only curative treatment for syndromes involving bone marrow failure and thalassemia. Interestingly, new conditioning regimes based on fludarabine have achieved very good results in these syndromes in recent years. Moreover, donors other than HLA-identical siblings are increasingly used, but this approach needs to be evaluated in larger studies.
